Tafamidis delays neurological progression comparably across Val30Met and non-Val30Met genotypes in transthyretin familial amyloid polyneuropathy

B. K. Gundapaneni\textsuperscript{a}, M. B. Sultan\textsuperscript{b}, D. J. Keohane\textsuperscript{b} and J. H. Schwartz\textsuperscript{c}

\textsuperscript{a}InVentiv Health Inc., Burlington, MA; \textsuperscript{b}Pfizer Inc, New York, NY; and \textsuperscript{c}Pfizer Inc, Groton, CT, USA

Keywords: amyloidosis, baseline severity, familial amyloid polyneuropathy, neurological progression, non-Val30Met, tafamidis, transthyretin, Val30Met

Received 16 May 2017
Accepted 2 November 2017

European Journal of Neurology 2018, 25:464–468
doi:10.1111/ene.13510

Background and purpose: To better characterize the effects of tafamidis in non-Val30Met patients with transthyretin familial amyloid polyneuropathy, this post hoc analysis compared the neurological results from a 12-month, open-label study of non-Val30Met versus Val30Met patients at month 12 from the 18-month, double-blind, placebo-controlled registration study. A baseline covariate adjusted analysis was used to control for differences in baseline neurological severity.

Methods: Neurological function was assessed using the Neuropathy Impairment Score – Lower Limbs (NIS-LL) in three cohorts: Val30Met tafamidis (n = 64), Val30Met placebo (n = 61) and non-Val30Met tafamidis (n = 21). The change in NIS-LL from baseline to month 12 for Val30Met and non-Val30Met tafamidis-treated patients was compared with the change from baseline at month 12 for Val30Met placebo-treated patients using a mixed-effects model for repeated measures (MMRM).

Results: The baseline adjusted mean (standard error) change in NIS-LL values at month 12 was similar for Val30Met [1.60 (0.78)] and non-Val30Met [1.62 (1.43)] tafamidis-treated patients and less than that observed in the Val30Met placebo-treated group [4.72 (0.77); \(P = 0.0055\) for Val30Met and \(P = 0.0592\) for non-Val30Met]. Based on the MMRM, the magnitude of change in both tafamidis-treated cohorts was similar across the range of observed baseline NIS-LL values, and was consistently less than that observed in the Val30Met placebo-treated group at month 12.

Conclusions: This baseline-adjusted analysis demonstrated that tafamidis treatment delayed neurological progression comparably in Val30Met and non-Val30Met patients across a range of baseline NIS-LL values. Neurological progression in these two genotype groups may be more similar than previously considered.

Background
Transthyretin familial amyloid polyneuropathy (TTR-FAP) is a rare, life-threatening, genetic disorder caused by \(TTR\) gene mutations that result in the formation of insoluble amyloid fibrils in peripheral nerves and organs [1]. Progressive tissue damage and the severely debilitating symptoms of peripheral and autonomic neuropathy, along with potential complications due to organ involvement, can significantly shorten life expectancy [2,3]. Clinical presentation can vary widely amongst patients depending on a number of factors, including age of onset and \(TTR\) gene mutation [3,4]. Of the \(TTR\) mutations, the Val30Met genotype is believed to be the most common and widely studied mutation and is associated with a
Val30Met mutations have more rapid disease progression 

answer the question of whether patients with non-
baseline disease severity, the current analysis helps to
patients treated with tafamidis [12]. By controlling for 
baseline disease severity was recently 
demonstrated in a post hoc analysis of Val30Met 
patients treated with tafamidis [12]. By controlling for 
baseline disease severity, the current analysis helps to 
answer the question of whether patients with non-
Val30Met mutations have more rapid disease progression than those with a Val30Met mutation.

Methods

Study design and participants

The combined intent-to-treat (ITT) data from the tafa-
midis 18-month, placebo-controlled, double-blind regis-
tration study in Val30Met patients (ClinicalTrials.gov 
identifier NCT00409175) and the 12-month open-label 
study in non-Val30Met patients (NCT00630864) were 
analysed based on treatment assignment in the original 
studies: Val30Met treated with tafamidis (n = 64), 
Val30Met treated with placebo (n = 61) and non-
Val30Met patients treated with tafamidis (n = 21; Asp38Ala, 
n = 1; Gly47Ala, n = 3; Leu58His, n = 4; Thr60Ala, 
n = 4; Phe64Leu, n = 4; Ser77Phe, n = 1; Ser77Tyr, 
n = 2; Ile107Val, n = 2) [8,14]. The ITT population for 
the Val30Met study was defined as all patients who 
received at least one dose of oral study medication (pla-
cebo or tafamidis meglumine 20 mg once daily) and 
had at least one post baseline assessment for both the 
Neuropathy Impairment Score – Lower Limbs (NIS-
LL) and the Norfolk Quality of Life – Diabetic Neu-opathy questionnaire, or discontinued the study due to 
death or liver transplant. For the non-Val30Met study, 
the ITT population included all patients who received at 
least one dose of oral tafamidis meglumine 20 mg 
[14]. Additional details on trial design and study partici-
ants are available in the primary publications of the 
registration study for Val30Met patients [8] and the 
open-label study for non-Val30Met patients [14]. Both 

Outcome measure

Neurological function was assessed using the NIS-LL 
[scores range from 0 (normal) to 88 (total impair-
ment)], a validated and sensitive measure of neurologi-

cal impairment in patients with TTR-FAP [15].

Statistical analysis

The change in NIS-LL from baseline to month 12 for 
Val30Met and non-Val30Met tafamidis-treated patients 
was compared with the change from baseline to month 
12 for Val30Met placebo patients using a mixed-effects 
model for repeated measures (MMRM), with change 
from baseline in NIS-LL as the dependent variable, 
treatment, visit and treatment-by-visit as fixed effects,
baseline NIS-LL as a covariate, and subject as a random effect in the model, using an unstructured covariance matrix. MMRM is an analysis method commonly used to assess effects in data collected from patients at multiple visits over time. The method is able to address the correlated observations that result from the repeated measurements of a patient progressing through a study over time. Partial data (e.g. from patients who do not fully complete the study) can also be included in the analysis.

Results

The baseline demographic and clinical characteristics of the Val30Met (placebo and tafamidis) and non-Val30Met (tafamidis) groups have been published previously [8,14]. The Val30Met and non-Val30Met patients were mostly from clinical sites in Portugal and the USA, respectively. All groups were predominantly Caucasian (~90%), comprising both male and female patients (Val30Met, 46.4% male; non-Val30Met, 61.9% male). Non-Val30Met tafamidis versus Val30Met tafamidis and placebo patients, respectively, were older [mean (SD) 63.1 (9.9) vs. 39.8 (12.7) and 38.4 (12.9) years] and had longer symptom duration [mean (SD) 64.7 (60.8) vs. 47.0 (48.4) and 34.7 (32.9) months] and more advanced neurological impairment [mean (SD) NIS-LL score 27.6 (24.7) vs. 8.4 (11.4) and 11.4 (13.5)] [8,14].

Baseline covariate adjusted change in NIS-LL scores from baseline to month 12 was analysed to assess treatment effect and account for differences in baseline disease severity amongst treatment groups. The baseline adjusted mean change scores in NIS-LL at month 12 were similar in Val30Met and non-Val30Met tafamidis-treated patients (1.60 vs. 1.62, respectively) and less than that observed in the Val30Met placebo group (4.72) (Table 1). The magnitude of separation from the Val30Met placebo group was statistically significant in the Val30Met tafamidis group ($P = 0.0055$) but not in the non-Val30Met tafamidis group ($P = 0.0592$), possibly due to the lower number of patients in the non-Val30Met group (Table 1).

Figure 1 shows the change from baseline across a range of baseline NIS-LL scores based on predicted values from the MMRM analysis. The magnitude of change in both the Val30Met and non-Val30Met tafamidis-treated patients was remarkably similar across the range of observed baseline NIS-LL values, and was consistently less than that observed in the Val30Met placebo group. The data also illustrate the impact of baseline NIS-LL on projected level of neurological progression: as baseline NIS-LL values increased, the predicted level of disease progression as measured by the change in NIS-LL from baseline to month 12 also increased. This relationship was evident regardless of treatment or genotype.

Discussion

This use of combined data from two clinical trials, whilst controlling for baseline disease severity, demonstrated that tafamidis delayed neurological progression comparably in non-Val30Met and Val30Met patients. The magnitude of neurological change from baseline to month 12 (based on predicted values from the MMRM analysis) in both Val30Met and non-Val30Met tafamidis-treated patients was remarkably similar across a range of baseline NIS-LL values and, in all cases, less than the change from baseline observed in the Val30Met placebo group. These comparable trajectories suggest that patients with non-Val30Met mutations may not progress faster than those with a Val30Met mutation. Differences in disease progression observed to date may be related to the fact that non-Val30Met patients are more probably sporadic cases and from non-endemic areas, where time to diagnosis is delayed due to a lack of recognition of the disease [16] and not related to an inherent

| Table 1 | Change from baseline in NIS-LL to month 12 for Val30Met and non-Val30Met groups |
|---------|----------------------------------------------------------------------------------|
|         | Tafamidis Val30Met | Placebo Val30Met | Tafamidis Val30Met versus placebo Val30Met | Tafamidis non-Val30Met versus placebo Val30Met |
| Baseline |                      |                  |                                             |                                               |
| $n$      | 64                   | 61               | –                                            | –                                              |
| Mean (SD)| 8.4 (11.4)           | 11.4 (13.5)      | –                                            | 27.6 (24.7)                                    |
| Month 12 change from baseline |                      |                  |                                              |                                               |
| $n$      | 49                   | 50               | –                                            | 18                                             |
| LS mean (SE) | 1.60 (0.78)       | 4.72 (0.77)      | –3.11 (1.10)                                 | 1.62 (1.43)                                    |
| 95% CI   | 0.05, 3.15           | 3.19, 6.25       | –5.30, –0.93                                 | —1.21, 4.45                                    |
| $P$ value | –                    | –                | 0.0055                                       | 0.0592                                         |

CI, confidence interval; LS mean, least squares mean; NIS-LL, Neuropathy Impairment Score – Lower Limbs.
This analysis provides further support for the benefit of tafamidis treatment in delaying disease progression in patients with TTR-FAP and has particular relevance for non-Val30Met tafamidis-treated patients where the original single-arm clinical study revealed some worsening of neurological function that was difficult to interpret in the absence of a control group [14]. The present post hoc analysis provided context by comparing the non-Val30Met data with a placebo group of another study (whilst adjusting for baseline disease severity) and, although not statistically significant, it demonstrated a slower neurological progression in non-Val30Met tafamidis-treated patients compared with the Val30Met placebo group, suggesting a beneficial effect of tafamidis. The predicted values from the MMRM analysis demonstrate the beneficial effect of tafamidis across a range of baseline NIS-LL values, and also highlight the importance of baseline disease severity in predicting natural disease progression and treatment response. As baseline disease burden increased, the rate of neurological progression in the subsequent 12 months also increased. This relationship held true regardless of genotype or treatment and was also demonstrated in another study based on longer-term data (the tafamidis registration study and the subsequent, open-label, extension studies; L. Amass, H. Li, B.K. Gundapaneni, J.H. Schwartz, D.J. Keohane, submitted).

The similar trajectories of neurological progression across tafamidis-treated Val30Met and non-Val30Met patients when controlling for baseline disease burden suggest that these two genotype groups are more similar than previously thought [3–5,17]. Despite the considerable phenotypic heterogeneity observed across non-Val30Met patients with TTR-FAP, the similarity between genotype groups is noteworthy, especially considering that the two clinical trials were conducted at different sites and under different protocols. Identifying and understanding the importance of key demographic and/or clinical characteristics (e.g. baseline disease severity) may ultimately reveal more similarities than differences between genotypes and become important considerations when studying disease progression and the impact of treatment.

Limitations

These results are limited by their post hoc nature and the combining of non-contemporaneous open-label, non-Val30Met study data with double-blind, placebo-controlled Val30Met data. They are also limited by the relatively small number of patients (comprising eight genotypes) in the non-Val30Met group.

Conclusions

This post hoc analysis of combined clinical data, whilst controlling for baseline disease severity, demonstrated similar trajectories in the Val30Met and non-Val30Met patients, suggesting that neurological progression in these two genotype groups may be more similar than previously considered. Further, the predicted values from the MMRM analysis illustrated the beneficial effects of tafamidis across a range of baseline NIS-LL values, and also highlighted the importance of baseline disease severity when evaluating the natural history of disease progression and the impact of treatment. This analysis demonstrated that treatment with tafamidis delayed neurological progression comparably in non-Val30Met and Val30Met patients.

Acknowledgements

Medical writing support was provided by Diane Hoffman, PhD, of Engage Scientific Solutions and was funded by Pfizer. This analysis was sponsored by Pfizer.

Disclosure of conflicts of interest

MB Sultan, DJ Keohane and JH Schwartz are employees of Pfizer and hold stock and/or stock options. BK Gundapaneni, an employee of inVentiv Health, was a paid contractor to Pfizer in providing
statistical support for this analysis and the development of this paper.

Supporting Information

Additional Supporting Information may be found in the online version of this article:

Box S1. List of independent ethics committees and institutional review boards.

References

1. Plante-Bordeneuve V. Update in the diagnosis and management of transthyretin familial amyloid polyneuropathy. J Neurol 2014; 261: 1227–1233.
2. Coelho T, Inês M, Concicâo I, Saramago P, de Carvalho M, Costa J. Temporal trends in transthyretin familial amyloid polyneuropathy survival over a century. Int J Clin Neurosci Ment Health 2016; 3: P130.
3. Mariani LL, Lozeron P, Theaudin M, et al. Genotype–phenotype correlation and course of transthyretin familial amyloid neuropathies in France. Ann Neurol 2015; 78: 901–916.
4. Coelho T, Maurer MS, Suhr OB. THAOS – the Transthyretin Amyloidosis Outcomes Survey: initial report on clinical manifestations in patients with hereditary and wild-type transthyretin amyloidosis. Curr Med Res Opin 2013; 29: 63–76.
5. Sekijima Y, Yoshida K, Tokuda T, Ikeda S. of website. http://www.ncbi.nlm.nih.gov/books/NBK1194/ (accessed 13 March 2017).
6. Coelho T, Waddington Cruz M, Fallet S, Carlsson M, Ong M-L. The natural history of transthyretin familial amyloidosis polyneuropathy: an analysis from the Transthyretin Amyloidosis Outcomes Survey. Presented at the XV International Symposium on Amyloidosis; Uppsala: Sweden, 3–7 July 2016.
7. Coelho T, Merlini G, Bulawa CE, et al. Mechanism of action and clinical application of tafamidis in hereditary transthyretin amyloidosis. Neurol Ther 2016; 5: 1–25.
8. Coelho T, Maia LF, Martins da Silva A, et al. Tafamidis for transthyretin familial amyloid polyneuropathy: a randomized, controlled trial. Neurology 2012; 79: 785–792.
9. Coelho T, Maia LF, Martins da Silva A, et al. Long-term effects of tafamidis for the treatment of transthyretin familial amyloid polyneuropathy. J Neurol 2013; 260: 2802–2814.
10. Barroso FA, Judge DP, Ebede B, et al. Long-term safety and efficacy of tafamidis for the treatment of hereditary transthyretin amyloid polyneuropathy: results up to 6 years. Amyloid 2017; 24: 194–204.
11. Ando Y, Sekijima Y, Obayashi K, et al. Effects of tafamidis treatment on transthyretin (TTR) stabilization, efficacy, and safety in Japanese patients with familial amyloid polyneuropathy (TTR-FAP) with Val30Met and non-Val30Met: a phase III, open-label study. J Neurol Sci 2016; 362: 266–271.
12. Waddington Cruz M, Amass L, Keohane D, Schwartz J, Li H, Gundapanenali B. Early intervention with tafamidis provides long term (5.5 year) delay of neurologic progression in transthyretin familial amyloid polyneuropathy. Amyloid 2016; 23: 178–183.
13. Keohane D, Schwartz J, Gundapanenali B, Stewart M, Amass L. Tafamidis delays disease progression in patients with early stage transthyretin familial amyloid polyneuropathy: additional supportive analyses from the pivotal trial. Amyloid 2017; 24: 30–36.
14. Merlini G, Plante-Bordeneuve V, Judge DP, et al. Effects of tafamidis on transthyretin stabilization and clinical outcomes in patients with non-Val30Met transthyretin amyloidosis. Cardiovasc Transl Res 2013; 6: 1011–1020.
15. Coelho T, Vinik A, Vinik EJ, Tripp T, Packman J, Grogan DR. Clinical measures in transthyretin familial amyloid polyneuropathy. Muscle Nerve 2017; 55: 323–332.
16. Parman Y, Adams D, Obici L, et al. Sixty years of transthyretin familial amyloid polyneuropathy (TTR-FAP) in Europe: where are we now? A European network approach to defining the epidemiology and management patterns for TTR-FAP. Curr Opin Neurol 2016; 29(Suppl. 1): S3–S13.
17. Suhr OB, Larsson M, Ericzon BG, Wilczek HE. Survival after transplantation in patients with mutations other than Val30Met: extracts from the FAP World Transplant Registry. Transplantation 2016; 100: 373–381.